---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-25-000935"
form_type: "8-K"
ticker: "ARTL"
cik: "0001621221"
company_name: "ARTELO BIOSCIENCES, INC."
filed_at: "2025-05-23T23:59:59+00:00"
generated_at: "2026-05-20T14:26:30.498427+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Artelo Biosciences notified by Nasdaq of equity deficiency; $652K vs $2.5M minimum

## Summary
- As of March 31, 2025, stockholders' equity was $652,000, below the $2.5M minimum required by Nasdaq Rule 5550(b)(1).
- Company has 45 days (until July 7, 2025) to submit a compliance plan to Nasdaq.
- If plan accepted, Nasdaq may grant up to 180 days (until Nov 18, 2025) to evidence compliance.
- No immediate impact on listing; common stock continues trading on Nasdaq pending review.
- Company evaluating options; no assurance that compliance plan will be accepted or delisting avoided.

## SEC filing metadata
- accession: 0001640334-25-000935
- form_type: 8-K
- ticker: ARTL
- cik: 0001621221
- company_name: ARTELO BIOSCIENCES, INC.
- filed_at: 2025-05-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621221/000164033425000935/0001640334-25-000935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621221/000164033425000935/artl_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-25-000935
- JSON: https://secwatch.observer/filing/0001640334-25-000935.json
- Plain text: https://secwatch.observer/filing/0001640334-25-000935.txt

## Key facts
- Listing & Compliance Notices
  ARTELO BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: May 22, 2025, Artelo Biosciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. On its Quarterly Report for the quarterly period ended March 31, 2025, the Company reported stockholders’ equity of $652,000, and, as a result, does not currently satisfy Nasdaq Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of t
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621221/000164033425000935/0001640334-25-000935-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.